A systematic review of validated methods for identifying erythema multiforme major/minor/not otherwise specified, Stevens–Johnson Syndrome, or toxic epidermal necrolysis using administrative and claims data

The Food and Drug Administration's (FDA) Mini‐Sentinel pilot program aims to conduct active surveillance to refine safety signals that emerge for marketed medical products. A key facet of this surveillance is to develop and understand the validity of algorithms for identifying health outcomes of interest (HOIs) from administrative and claims data. This paper summarizes the process and findings of the algorithm review of erythema multiforme and related conditions.

[1]  R. Carnahan,et al.  Mini‐Sentinel's systematic reviews of validated methods for identifying health outcomes using administrative and claims data: methods and lessons learned , 2012, Pharmacoepidemiology and drug safety.

[2]  L. French,et al.  Toxic epidermal necrolysis and Stevens-Johnson syndrome , 2010, Orphanet journal of rare diseases.

[3]  R. Kagan,et al.  Successfully Changing an ICD-9 Diagnosis Code: The ABA Experience for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis , 2010, Journal of burn care & research : official publication of the American Burn Association.

[4]  C. Gau,et al.  The Association Between Carbamazepine and Valproate and Adverse Cutaneous Drug Reactions in Patients With Bipolar Disorder: A Nested Matched Case-Control Study , 2008, Journal of clinical psychopharmacology.

[5]  P. Williams,et al.  Erythema multiforme. , 2006, American family physician.

[6]  R. Stern.  Utilization of hospital and outpatient care for adverse cutaneous reactions to medications , 2005, Pharmacoepidemiology and drug safety.

[7]  C. Scully,et al.  Number IV Erythema multiforme , 2005 .

[8]  C. Scully,et al.  Mucosal disease series. Number IV. Erythema multiforme. , 2005, Oral diseases.

[9]  Manuel Gomez,et al.  Evaluation of the Extent of Under-Reporting of Serious Adverse Drug Reactions , 2004, Drug safety.

[10]  R. Stern,et al.  The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: a multinational perspective. , 2003, The Journal of rheumatology.

[11]  R. Rogers,et al.  Oral manifestations of erythema multiforme. , 2003, Dermatologic clinics.

[12]  L. Naldi,et al.  Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. , 2002, Archives of dermatology.

[13]  B. Strom,et al.  Data validity issues in using claims data , 2001, Pharmacoepidemiology and drug safety.

[14]  J. Roujeau,et al.  Erythema multiforme with mucous membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes. , 1995, Archives of dermatology.

[15]  B. Strom,et al.  A population-based study of Stevens-Johnson syndrome. Incidence and antecedent drug exposures. , 1991, Archives of dermatology.

[16]  R. Stern,et al.  Using a claims database to investigate drug-induced Stevens-Johnson syndrome. , 1991, Statistics in medicine.

[17]  R. Stern,et al.  The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. , 1990 .